type1diabetesSleep1childNCT05762783
The Importance of Sleep for Diabetes Associated Tasks and Outcomes
An observational study of type1diabetes and Sleep Disturbance, run by Steno Diabetes Center Copenhagen at 1 site in Denmark.
Trial summary
Adolescents with type 1 diabetes (T1D) experience more disturbed sleep compared to their healthy peers, especially because they tend to spend less time in deep sleep, the most restoring part of sleep, potentially impacting diabetes management. Read more about this study
- Who is it for?
- Ages 6 to 17 years
- Conditions the study is for
- type1diabetes, Sleep Disturbance
- How many people
- 77 participants
- Where
- 1 siteDenmark
- Study dates
- 27 Mar 2023to 16 Apr 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Children and adolescents with type 1 diabetes (T1D) 6 to 17 years old, which have had the disease for over 6 months and use both an insulin pump and a continuous glucose monitor. One or both parents and healthy siblings are also included, but this is not a demand.
Who may be able to join
- Type 1 diabetes for > 6 months
- Use of both insulin pump and continuous glucose monitor
Who cannot join
- Severe psychiatric diseases using ICD-10 codes (e.g. ADHD, autism spectrum disorder, eating disorders, retarded mental development)
- Unwillingness to participate and inability to read and understand Danish or English.
Trial locations and contacts
1 site in 1 country.
About this study
Adolescents with type 1 diabetes (T1D) experience more disturbed sleep compared to their healthy peers, especially because they tend to spend less time in deep sleep, the most restoring part of sleep, potentially impacting diabetes management. Disturbed sleep may adversely affect diabetes management which requires day-to-day decision-making, emotional and behavioural regulation, attention, and planning. Despite a massive increase in new technology, more than 50% of adolescents do not reach their glycaemic target. Lack of sleep impairing diabetes management including blood glucose monitoring may play an important role in reaching the goal. For approximately 4000 children and adolescents in Denmark living with T1D, sleep disturbances may therefore account for short and long-term diabetes complications.
Our overall aims are to investigate: (1) If and how glycaemic variability (GV) influences sleep quality and sleep stages and (2) if and how poor sleep quality influences time-in-range (TIR), time-above-range (TAR) and time-below-range (TBR) the following day.
Read the detailed description
Background: Sleep distrubances are increasing among adolescents in Denmark. In 2017, a large health survey reported that 14.9 % of the 16-24 year-olds ( n= 7,627) had sleep problems over the last two weeks-an alarmingly high increase of 33.3% since the first survey in 2010. Adolescents with type 1 diabetes (T1D) experience more disturbed sleep compared to their healthy peers, especially because they tend to spend less time in deep sleep, the most restoring part of sleep. Disturbed sleep may adversely affect diabetes management which requires daily blood glucose monitoring (BGM), day-to-day decision-making, emotional and behavioural regulation, attention and planning (behavioural pathway). Diabetes management plays an important role in reaching glycemic targets and the worsening glycemic outcome may impact sleep and start a vicious circle. Currently, >50% of adolescents do not reach the glycemic target. Furthermore, the disturbance of circadian rhythmicity may in itself have metabolic consequences (metabolic pathway). Disturbed sleep may contribute to the 40% increased risk of psychiatric disease (anxiety, depression and eating disorders) associated with childhood diabetes. A link between psychiatric disease, stress and sleep has been confirmed. For the approximately 4000 children and adolescents in Denmark living with T1D, this means sleep problems may contribute negatively and increase the risk of short and long-term diabetes complications.
Over the past decades, the use of technology such as insulin pumps and continuous glucose monitors (CGM) in T1D treatment has increased dramatically, but still far from all reaches glycemic targets. This may, in part, be explained by the vicious circle and the additional disturbances from alarms and difficulties in initiating sleep due to itching or irritation from having devices attached to the body. The more beneficial effect on sleep from advanced insulin pumps like hybrid closed loop systems with less glycemic variability and fewer alarms overnight, has yet to be proved in children and adolescents.
The term sleep is defined as sleep quality and duration. Disturbed sleep is defined as too short or long duration for age based on guidelines from the American Academy of Sleep Medicine (AASM) and/or poor quality sleep. The ability to be more resilient, have better coping strategies and more self-compassion may impact your sleep through the influence on rumination, reducing sleep latency (period from going to bed to falling asleep) and duration of wake-up periods, why resilience, coping and compassion are potentially modifiable factors. Other factors like social activities and media uses are important factors associated with changes in circadian rhythmicity, sleep length, sleep disturbances and poorer daytime performance. Furthermore, poor glycemic control is associated with sleep disorders like obstructive sleep apnea.
The golden standard for sleep assessment is polysomnography (PSG), but it is limited because it (1) typically provides only 1-2 nights of information about a child's sleep, (2) requires in some cases observation outside the natural environment in a sleep lab and (3) has significant financial costs. We have access to a new home sleep test with eye movement detection (HST REM+) from Somnomedics GmbH which is validated against PSG in adults. The HST REM+ is a simplified PSG which measures sleep architecture (sleep stages) with three electrodes in the forehead and one behind the ear. The HST REM+ can make measurements for up to 5 nights at home with a tablet showing how to apply the electrodes. The HST REM+ is combined with ActiGraph wGT3X-BT (AG), a small wristwatch measuring movements and validated against PSG in adolescents. With the majority of children being treated with continuous glucose monitoring (CGM) and insulin pumps, we have the unique opportunity to combine data from these different objective sleep measures and thorough diabetes management data from downloads from insulin pump and CGM. This opens for the opportunity to study 24/7 variation in diabetes management and glycemic outcome including device alarm frequency and relate this to the current and previous night sleep. Additionally, we are able to study how advanced insulin pumps including hybrids closed loop systems impact sleep parameters such as sleep duration, sleep stages, sleep efficiency and sleep latency.
Our overall aims are to investigate: (1) If and how glycaemic variability influences sleep quality and sleep stages and (2) if and how poor sleep quality influences time-in-range (TIR), time-above-range (TAR) and time-below-range (TBR) the following day.
Main hypothesis
- Glycaemic variability is negatively associated with sleep quality and time spent in deep sleep (sleep stage N3+N4)
- Sleep quality is positively associated with time in range (TIR) the following day
Study design: Observational, cross-sectional study. Methods: Children and adolescents with T1D are recruited from the Diabetes Outpatient Clinic, Steno Diabetes Center Copenhagen (SDCC), providing approximately 750 of the 900 children and adolescents using CGM and insulin pumps. One or both parents are invited to participate as well as healthy siblings as controls. The families are recruited from a notice in the waiting room, from the SDCC webpage and asked to participate during out-patient visits, where written and oral information are given. Questionnaires and clinical parameters will be collected. One-week simultaneous observation at home with AG, a sleep diary (which they receive on their mobile device after each night), HST REM+ (5 days) and diabetes management (insulin pump and CGM) will be offered. Eligibility criteria: Participants are included if they are 6-17 years of age with > 6 months T1D duration and are using an insulin pump and CGM (all types). Exclusion criteria are severe psychiatric diseases using ICD-10 codes (e.g. ADHD, autism spectrum disorder, eating disorders, retarded mental development), unwillingness to participate and inability to read and understand Danish or English. Primary Outcome WP1: Sleep quality is defined as % time in deep sleep stages (N3 and N4). Secondary outcomes: Deep sleep (minutes), REM sleep % and minutes, sleep quality (AG), TST (HST REM+ and AG), sleep score from the Scandinavian Sleep Questionnaire - Children and Adolescents sleep (SSQ-CA). Exposure: GV during the night. Additionally, as exploratory analysis: Diabetes-specific stressors e.g., alarms and fear of hypoglycemia, resilience, quality of life, strengths and difficulties and stress in the caregiver. Covariates: Diabetes duration, treatment modality, age and gender. Primary outcome WP2: Daytime TIR. Secondary outcomes: a) Glycaemic outcomes (Daytime TAR and TBR, Day + night TIR, TBR, TAR, HbA1c, Glycaemic risk index, mean glucose, GV and standard deviation (SD)); b) diabetes-management (use of bolus-guide including blood glucose and carbohydrate from pump download). Exposure: Sleep quality is defined as % time in deep sleep stages (N3 and N4). Additionally, sleep quality (SSQ-CA and AG), REM sleep (HST REM+). Covariates: Diabetes duration, treatment modality, age, gender. Statistics/power: Statistical methods will include descriptive statistics, T-test, Spearman's correlation, RASCH modelling of questionnaire data. All variables in the models will be tested for effect size using univariate analysis. Multiple regression models will include explanatory variables and covariates depending on effect size and importance. Inverse probability weighting will be used to examine selection bias due to non-participation Regarding hypothesis 1: To detect a change of 3 % in deep sleep (N3) with an SD of 7 %, we have a power of 80% if 43 participate in the study (significance level of 5%). Regarding hypothesis 2: To detect a change of 5 % in TIR with an SD of 12 %, we have a power of 80% if 45 participate in the study (significance level of 5%).
- Conditions
- type1diabetes, Sleep Disturbance
- Keywords
- type 1 diabetes, children and adolescents, sleep, continuos glucose monitor, diabetes management, sleep disturbance
- Medical subject headings
- Parasomnias, Diabetes Mellitus, Type 1
What is being measured
The primary outcome is the main question the study is designed to answer.
Sleep quality
% of total sleep time in deep sleep (stage N3 and N4)
Measured: In the the study periode (one to maksimum five nights)
Daytime time-in-range (TIR)
3,9-10 mmol/L
Measured: In the study periode (7 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Mar 2023
- Study start27 Mar 2023
- Primary completion16 Apr 2024
- Study completion16 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for type1diabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 77 participants (actual)
Sponsor and investigators
- Lead sponsor
- Steno Diabetes Center Copenhagen
- Sponsor type
- University, hospital or other
- Collaborators
- Danish Diabetes Academy, Danish Center for Sleep Medicine, University of Copenhagen, Herlev Hospital
- Responsible party
- Sponsor
- Investigators
- Jannet Svensson, Professor, Principal investigator, Steno Diabetes Center Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05762783
- Sponsor's protocol ID
- T_023
- Acronym
- Sleep1child
- Status last verified
- Apr 2024
- First submitted
- 16 Feb 2023
- Last updated
- 18 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Importance of Sleep for Diabetes Associated Tasks and Outcomes
- ClinicalTrials.gov ID
- NCT05762783
- Acronym / sponsor ID
- Sleep1child / T_023
- Conditions
- type1diabetes, Sleep Disturbance
- Keywords
- type 1 diabetes, children and adolescents, sleep, continuos glucose monitor, diabetes management, sleep disturbance
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 77 participants (actual)
- Lead sponsor
- Steno Diabetes Center CopenhagenUniversity, hospital or other
- Collaborators
- Danish Diabetes Academy, Danish Center for Sleep Medicine, University of Copenhagen, Herlev Hospital
- Study start
- 27 Mar 2023 (actual)
- Primary completion
- 16 Apr 2024 (actual)
- Study completion
- 16 Apr 2024 (actual)
- First posted
- 10 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Adolescents with type 1 diabetes (T1D) experience more disturbed sleep compared to their healthy peers, especially because they tend to spend less time in deep sleep, the most restoring part of sleep, potentially impacting diabetes management. Disturbed sleep may adversely affect diabetes management which requires day-to-day decision-making, emotional and behavioural regulation, attention, and planning. Despite a massive increase in new technology, more than 50% of adolescents do not reach their glycaemic target. Lack of sleep impairing diabetes management including blood glucose monitoring may play an important role in reaching the goal. For approximately 4000 children and adolescents in Denmark living with T1D, sleep disturbances may therefore account for short and long-term diabetes complications.
Our overall aims are to investigate: (1) If and how glycaemic variability (GV) influences sleep quality and sleep stages and (2) if and how poor sleep quality influences time-in-range (TIR), time-above-range (TAR) and time-below-range (TBR) the following day.
Detailed description
Background: Sleep distrubances are increasing among adolescents in Denmark. In 2017, a large health survey reported that 14.9 % of the 16-24 year-olds ( n= 7,627) had sleep problems over the last two weeks-an alarmingly high increase of 33.3% since the first survey in 2010. Adolescents with type 1 diabetes (T1D) experience more disturbed sleep compared to their healthy peers, especially because they tend to spend less time in deep sleep, the most restoring part of sleep. Disturbed sleep may adversely affect diabetes management which requires daily blood glucose monitoring (BGM), day-to-day decision-making, emotional and behavioural regulation, attention and planning (behavioural pathway). Diabetes management plays an important role in reaching glycemic targets and the worsening glycemic outcome may impact sleep and start a vicious circle. Currently, >50% of adolescents do not reach the glycemic target. Furthermore, the disturbance of circadian rhythmicity may in itself have metabolic consequences (metabolic pathway). Disturbed sleep may contribute to the 40% increased risk of psychiatric disease (anxiety, depression and eating disorders) associated with childhood diabetes. A link between psychiatric disease, stress and sleep has been confirmed. For the approximately 4000 children and adolescents in Denmark living with T1D, this means sleep problems may contribute negatively and increase the risk of short and long-term diabetes complications.
Over the past decades, the use of technology such as insulin pumps and continuous glucose monitors (CGM) in T1D treatment has increased dramatically, but still far from all reaches glycemic targets. This may, in part, be explained by the vicious circle and the additional disturbances from alarms and difficulties in initiating sleep due to itching or irritation from having devices attached to the body. The more beneficial effect on sleep from advanced insulin pumps like hybrid closed loop systems with less glycemic variability and fewer alarms overnight, has yet to be proved in children and adolescents.
The term sleep is defined as sleep quality and duration. Disturbed sleep is defined as too short or long duration for age based on guidelines from the American Academy of Sleep Medicine (AASM) and/or poor quality sleep. The ability to be more resilient, have better coping strategies and more self-compassion may impact your sleep through the influence on rumination, reducing sleep latency (period from going to bed to falling asleep) and duration of wake-up periods, why resilience, coping and compassion are potentially modifiable factors. Other factors like social activities and media uses are important factors associated with changes in circadian rhythmicity, sleep length, sleep disturbances and poorer daytime performance. Furthermore, poor glycemic control is associated with sleep disorders like obstructive sleep apnea.
The golden standard for sleep assessment is polysomnography (PSG), but it is limited because it (1) typically provides only 1-2 nights of information about a child's sleep, (2) requires in some cases observation outside the natural environment in a sleep lab and (3) has significant financial costs. We have access to a new home sleep test with eye movement detection (HST REM+) from Somnomedics GmbH which is validated against PSG in adults. The HST REM+ is a simplified PSG which measures sleep architecture (sleep stages) with three electrodes in the forehead and one behind the ear. The HST REM+ can make measurements for up to 5 nights at home with a tablet showing how to apply the electrodes. The HST REM+ is combined with ActiGraph wGT3X-BT (AG), a small wristwatch measuring movements and validated against PSG in adolescents. With the majority of children being treated with continuous glucose monitoring (CGM) and insulin pumps, we have the unique opportunity to combine data from these different objective sleep measures and thorough diabetes management data from downloads from insulin pump and CGM. This opens for the opportunity to study 24/7 variation in diabetes management and glycemic outcome including device alarm frequency and relate this to the current and previous night sleep. Additionally, we are able to study how advanced insulin pumps including hybrids closed loop systems impact sleep parameters such as sleep duration, sleep stages, sleep efficiency and sleep latency.
Our overall aims are to investigate: (1) If and how glycaemic variability influences sleep quality and sleep stages and (2) if and how poor sleep quality influences time-in-range (TIR), time-above-range (TAR) and time-below-range (TBR) the following day.
Main hypothesis
- Glycaemic variability is negatively associated with sleep quality and time spent in deep sleep (sleep stage N3+N4)
- Sleep quality is positively associated with time in range (TIR) the following day
Study design: Observational, cross-sectional study. Methods: Children and adolescents with T1D are recruited from the Diabetes Outpatient Clinic, Steno Diabetes Center Copenhagen (SDCC), providing approximately 750 of the 900 children and adolescents using CGM and insulin pumps. One or both parents are invited to participate as well as healthy siblings as controls. The families are recruited from a notice in the waiting room, from the SDCC webpage and asked to participate during out-patient visits, where written and oral information are given. Questionnaires and clinical parameters will be collected. One-week simultaneous observation at home with AG, a sleep diary (which they receive on their mobile device after each night), HST REM+ (5 days) and diabetes management (insulin pump and CGM) will be offered. Eligibility criteria: Participants are included if they are 6-17 years of age with > 6 months T1D duration and are using an insulin pump and CGM (all types). Exclusion criteria are severe psychiatric diseases using ICD-10 codes (e.g. ADHD, autism spectrum disorder, eating disorders, retarded mental development), unwillingness to participate and inability to read and understand Danish or English. Primary Outcome WP1: Sleep quality is defined as % time in deep sleep stages (N3 and N4). Secondary outcomes: Deep sleep (minutes), REM sleep % and minutes, sleep quality (AG), TST (HST REM+ and AG), sleep score from the Scandinavian Sleep Questionnaire - Children and Adolescents sleep (SSQ-CA). Exposure: GV during the night. Additionally, as exploratory analysis: Diabetes-specific stressors e.g., alarms and fear of hypoglycemia, resilience, quality of life, strengths and difficulties and stress in the caregiver. Covariates: Diabetes duration, treatment modality, age and gender. Primary outcome WP2: Daytime TIR. Secondary outcomes: a) Glycaemic outcomes (Daytime TAR and TBR, Day + night TIR, TBR, TAR, HbA1c, Glycaemic risk index, mean glucose, GV and standard deviation (SD)); b) diabetes-management (use of bolus-guide including blood glucose and carbohydrate from pump download). Exposure: Sleep quality is defined as % time in deep sleep stages (N3 and N4). Additionally, sleep quality (SSQ-CA and AG), REM sleep (HST REM+). Covariates: Diabetes duration, treatment modality, age, gender. Statistics/power: Statistical methods will include descriptive statistics, T-test, Spearman's correlation, RASCH modelling of questionnaire data. All variables in the models will be tested for effect size using univariate analysis. Multiple regression models will include explanatory variables and covariates depending on effect size and importance. Inverse probability weighting will be used to examine selection bias due to non-participation Regarding hypothesis 1: To detect a change of 3 % in deep sleep (N3) with an SD of 7 %, we have a power of 80% if 43 participate in the study (significance level of 5%). Regarding hypothesis 2: To detect a change of 5 % in TIR with an SD of 12 %, we have a power of 80% if 45 participate in the study (significance level of 5%).
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Children and adolescents with type 1 diabetes (T1D) 6 to 17 years old, which have had the disease for over 6 months and use both an insulin pump and a continuous glucose monitor. One or both parents and healthy siblings are also included, but this is not a demand.
Key inclusion criteria (2 listed)
- Type 1 diabetes for > 6 months
- Use of both insulin pump and continuous glucose monitor
Key exclusion criteria (2 listed)
- Severe psychiatric diseases using ICD-10 codes (e.g. ADHD, autism spectrum disorder, eating disorders, retarded mental development)
- Unwillingness to participate and inability to read and understand Danish or English.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Sleep quality
Time frame: In the the study periode (one to maksimum five nights)
% of total sleep time in deep sleep (stage N3 and N4)
Daytime time-in-range (TIR)
Time frame: In the study periode (7 days)
3,9-10 mmol/L
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Apr 2024.
Related trials for type1diabetes
Active, not recruitingPhase 4
Diabetes in African Youth
type1diabetes
Active, not recruitingPhase 2
Probiotics in Newly Diagnosed T1D
Type 1 Diabetes, Type1diabetes
RecruitingObservational study
Crosstalk Between Mucosal-Associated Invariant T (MAIT) Cells and the Gut Microbiota and Mucosa in the Development of Type 1 Diabetes in Children
Type1diabetes
Active, not recruitingPhase 2
Reducing Innate Inflammation in New Onset Type 1 Diabetes
Type 1 Diabetes, type1diabetes
Recruiting
Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)
Non-Nutritive Sweetener, Type 1 Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Jannet Svensson, Professor principal investigator
Steno Diabetes Center Copenhagen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of type1diabetes and Sleep Disturbance, run by Steno Diabetes Center Copenhagen at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sleep quality (time frame: In the the study periode (one to maksimum five nights)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2024.